RE:RE:CAR-T updatePreceeding the August 2022 announcement of Roche and Poseida's collaboration to develop allogeneic CAR-T therapies directed to hematologic malignancies, came ONCY's findings showing the addition of pelareorep to CAR-T therapy.
In April 2022 ONCY demonstrated that pelareorep was synergistic with CAR-T cell therapy in solid tumors,
April 14, 2022 - Oncolytics Biotech® Announces Publication of Preclinical Data Demonstrating the Synergistic Anti-Cancer Activity of Pelareorep Combined with CAR T Cell Therapy in Solid Tumors in Science Translational Medicine
- Combining CAR T cells with pelareorep prevented antigen escape by creating CAR T cells with dual specificity through a novel mechanism
-Loading CAR T cells with pelareorep led to dramatic improvements in their persistence and anti-cancer activity as well as cures in multiple murine solid tumor models
https://www.prnewswire.com/news-releases/oncolytics-biotech-announces-publication-of-preclinical-data-demonstrating-the-synergistic-anti-cancer-activity-of-pelareorep-combined-with-car-t-cell-therapy-in-solid-tumors-in-science-translational-medicine-301525571.html